Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Catabasis Pharmaceuticals stock | $1.89

Own Catabasis Pharmaceuticals stock in just a few minutes.

Fact checked

Catabasis Pharmaceuticals, Inc is a biotechnology business based in the US. Catabasis Pharmaceuticals shares (CATB) are listed on the NASDAQ and all prices are listed in US Dollars. Catabasis Pharmaceuticals employs 27 staff and has a market cap (total outstanding shares value) of USD$45.2 million.

How to buy shares in Catabasis Pharmaceuticals

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Catabasis Pharmaceuticals. Find the stock by name or ticker symbol: CATB. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Catabasis Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$1.89, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Catabasis Pharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Catabasis Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Catabasis Pharmaceuticals share price

Use our graph to track the performance of CATB stocks over time.

Catabasis Pharmaceuticals shares at a glance

Information last updated 2020-12-26.
Latest market closeUSD$1.89
52-week rangeUSD$1.25 - USD$8.59
50-day moving average USD$1.7576
200-day moving average USD$5.1072
Wall St. target priceUSD$24
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-2.807

Buy Catabasis Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Catabasis Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Catabasis Pharmaceuticals price performance over time

Historical closes compared with the close of $1.89 from 2020-12-09

1 week (2021-01-07) -22.54%
1 month (2020-12-17) -10.43%
3 months (2020-10-16) -69.81%
6 months (2020-07-16) -70.97%
1 year (2020-01-16) -73.00%
2 years (2019-01-16) -69.71%
3 years (2018-01-16) 26.85%
5 years (2016-01-15) 5.51

Catabasis Pharmaceuticals financials

Gross profit TTM USD$0
Return on assets TTM -43.71%
Return on equity TTM -79.77%
Profit margin 0%
Book value $2.456
Market capitalisation USD$45.2 million

TTM: trailing 12 months

Shorting Catabasis Pharmaceuticals shares

There are currently 469,953 Catabasis Pharmaceuticals shares held short by investors – that's known as Catabasis Pharmaceuticals's "short interest". This figure is 5.8% up from 444,224 last month.

There are a few different ways that this level of interest in shorting Catabasis Pharmaceuticals shares can be evaluated.

Catabasis Pharmaceuticals's "short interest ratio" (SIR)

Catabasis Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Catabasis Pharmaceuticals shares currently shorted divided by the average quantity of Catabasis Pharmaceuticals shares traded daily (recently around 2.9 million). Catabasis Pharmaceuticals's SIR currently stands at 0.16. In other words for every 100,000 Catabasis Pharmaceuticals shares traded daily on the market, roughly 160 shares are currently held short.

However Catabasis Pharmaceuticals's short interest can also be evaluated against the total number of Catabasis Pharmaceuticals shares, or, against the total number of tradable Catabasis Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Catabasis Pharmaceuticals's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Catabasis Pharmaceuticals shares in existence, roughly 100 shares are currently held short) or 0.1126% of the tradable shares (for every 100,000 tradable Catabasis Pharmaceuticals shares, roughly 113 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Catabasis Pharmaceuticals.

Find out more about how you can short Catabasis Pharmaceuticals stock.

Catabasis Pharmaceuticals share dividends

We're not expecting Catabasis Pharmaceuticals to pay a dividend over the next 12 months.

Have Catabasis Pharmaceuticals's shares ever split?

Catabasis Pharmaceuticals's shares were split on a 1:10 basis on 31 December 2018. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Catabasis Pharmaceuticals shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Catabasis Pharmaceuticals shares which in turn could have impacted Catabasis Pharmaceuticals's share price.

Catabasis Pharmaceuticals share price volatility

Over the last 12 months, Catabasis Pharmaceuticals's shares have ranged in value from as little as $1.25 up to $8.59. A popular way to gauge a stock's volatility is its "beta".

CATB.US volatility(beta: 2.12)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Catabasis Pharmaceuticals's is 2.1202. This would suggest that Catabasis Pharmaceuticals's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Catabasis Pharmaceuticals overview

Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. Its lead product candidate is edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activated B cells, which is in Phase III clinical trial for the treatment of duchenne muscular dystrophy (DMD). The company is also developing CAT-5571 for the treatment of cystic fibrosis. Catabasis Pharmaceuticals, Inc. has a preclinical research collaboration with the Jain Foundation to study edasalonexent in dysferlinopathy; and an agreement with the Bill & Melinda Gates Medical Research Institute to study CAT-5571 in drug-sensitive and drug-resistant tuberculosis. The company was founded in 2008 and is based in Boston, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site